BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1087 related articles for article (PubMed ID: 24412052)

  • 21. Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance.
    Gopalan V; Pillai S; Ebrahimi F; Salajegheh A; Lam TC; Le TK; Langsford N; Ho YH; Smith RA; Lam AK
    Mol Carcinog; 2014 Feb; 53 Suppl 1():E36-44. PubMed ID: 24009195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression levels of miR-143-3p and -424-5p in colorectal cancer and their clinical significance.
    Sahami-Fard MH; Kheirandish S; Sheikhha MH
    Cancer Biomark; 2019; 24(3):291-297. PubMed ID: 30883340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC).
    Zhang T; Cai X; Li Q; Xue P; Chen Z; Dong X; Xue Y
    Oncotarget; 2016 Jul; 7(27):42225-42240. PubMed ID: 27302926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expressions of cancer-associated genes and their regulatory miRNAs in colorectal carcinoma.
    Kara M; Yumrutas O; Ozcan O; Celik OI; Bozgeyik E; Bozgeyik I; Tasdemir S
    Gene; 2015 Aug; 567(1):81-6. PubMed ID: 25925209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MTUS1 and its targeting miRNAs in colorectal carcinoma: significant associations.
    Ozcan O; Kara M; Yumrutas O; Bozgeyik E; Bozgeyik I; Celik OI
    Tumour Biol; 2016 May; 37(5):6637-45. PubMed ID: 26643896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation.
    Suto T; Yokobori T; Yajima R; Morita H; Fujii T; Yamaguchi S; Altan B; Tsutsumi S; Asao T; Kuwano H
    Carcinogenesis; 2015 Mar; 36(3):338-45. PubMed ID: 25503932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low expression of microRNA-126 is associated with poor prognosis in colorectal cancer.
    Liu Y; Zhou Y; Feng X; Yang P; Yang J; An P; Wang H; Ye S; Yu C; He Y; Luo H
    Genes Chromosomes Cancer; 2014 Apr; 53(4):358-65. PubMed ID: 24532280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation.
    Chen X; Shi K; Wang Y; Song M; Zhou W; Tu H; Lin Z
    Oncotarget; 2015 Nov; 6(35):37544-56. PubMed ID: 26462034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased Expression of MIR-134 and its Clinical Significance in Human Colorectal Cancer.
    Xie Y; Song J; Zong Q; Wang A; Yang Y; Liu F; Meng X
    Hepatogastroenterology; 2015 May; 62(139):615-9. PubMed ID: 26897940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma.
    Wang Q; Huang Z; Guo W; Ni S; Xiao X; Wang L; Huang D; Tan C; Xu Q; Zha R; Zhang J; Sheng W; He X; Du X
    Clin Cancer Res; 2014 Mar; 20(5):1146-57. PubMed ID: 24327274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer.
    Wang F; Ma YL; Zhang P; Shen TY; Shi CZ; Yang YZ; Moyer MP; Zhang HZ; Chen HQ; Liang Y; Qin HL
    J Pathol; 2013 Jan; 229(1):12-24. PubMed ID: 22821729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-511-5p functions as a tumor suppressor and a predictive of prognosis in colorectal cancer by directly targeting GPR116.
    Wang C; Fan HQ; Zhang YW
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6119-6130. PubMed ID: 31364112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downregulation of microRNA-409-3p promotes aggressiveness and metastasis in colorectal cancer: an indication for personalized medicine.
    Liu M; Xu A; Yuan X; Zhang Q; Fang T; Wang W; Li C
    J Transl Med; 2015 Jun; 13():195. PubMed ID: 26084278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer.
    Liu M; Zhi Q; Wang W; Zhang Q; Fang T; Ma Q
    Biomed Pharmacother; 2015 Feb; 69():214-20. PubMed ID: 25661360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5.
    Wang D; Li Y; Zhang C; Li X; Yu J
    J Cell Biochem; 2018 Feb; 119(2):1755-1766. PubMed ID: 28786533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR.
    Li W; Chang J; Wang S; Liu X; Peng J; Huang D; Sun M; Chen Z; Zhang W; Guo W; Li J
    Oncotarget; 2015 Sep; 6(27):24448-62. PubMed ID: 26259252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-126 functions as a tumor suppressor in colorectal cancer cells by targeting CXCR4 via the AKT and ERK1/2 signaling pathways.
    Liu Y; Zhou Y; Feng X; An P; Quan X; Wang H; Ye S; Yu C; He Y; Luo H
    Int J Oncol; 2014 Jan; 44(1):203-10. PubMed ID: 24189753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer.
    Han Y; Kuang Y; Xue X; Guo X; Li P; Wang X; Guo X; Yuan B; Zhi Q; Zhao H
    Biomed Pharmacother; 2014 Jun; 68(5):497-505. PubMed ID: 24972723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells.
    Almeida MI; Nicoloso MS; Zeng L; Ivan C; Spizzo R; GafĂ  R; Xiao L; Zhang X; Vannini I; Fanini F; Fabbri M; Lanza G; Reis RM; Zweidler-McKay PA; Calin GA
    Gastroenterology; 2012 Apr; 142(4):886-896.e9. PubMed ID: 22240480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-378a-5p targets cyclin G2 to inhibit fusion and differentiation in BeWo cells.
    Nadeem U; Ye G; Salem M; Peng C
    Biol Reprod; 2014 Sep; 91(3):76. PubMed ID: 25122062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.